Glenmark Eyes Blockbuster Status For First In-House Biologic
Executive Summary
Indian drug firm Glenmark Pharmaceuticals says it’s launching a Phase 2b clinical trial for its first biologic developed in-house, a medicine to treat atopic dermatitis that the company believes may have blockbuster potential.
You may also be interested in...
Glenmark Sets Sights On Regional Out-Licensing, Lot Riding On US Rhinitis NDA
With a basket of interesting R&D assets in hand, India’s Glenmark says it is pursuing regional out-licensing deals, including in Japan and China, for some of its molecules. Expectations are also running high on the firm’s first US NDA submission for seasonal allergic rhinitis.
Glenmark Progresses Novel Pain Asset With Partnering In Mind
Glenmark is moving ahead with studies for its inhibitor of mPGES-1 amid cautious optimism. Pain management is, however, not a core thrust for the Indian firm and it hopes to out-license the potential first-in-class molecule at some stage.
Amid US Challenges, Will Glenmark’s R&D Pipeline Deliver?
Glenmark reported subdued Q2 earnings, with the management predicting that the US business environment could stay challenging for at least two years. The firm, though, was upbeat on the potential of certain R&D assets, with a monoclonal antibody seen as “most promising” from an out-licensing perspective and a combination for seasonal allergic rhinitis set for a US NDA filing early next year.